Magnesium and Metabolic Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00603499|
Recruitment Status : Completed
First Posted : January 29, 2008
Last Update Posted : January 29, 2008
Objective : to test the BP lowering-effect of oral magnesium supplementation, as magnesium chloride (MgCl2) solution, 2.5 g daily, in uncomplicated hypertensive type 2 diabetic subjects with decreased serum magnesium levels Design : Randomised double blind placebo controlled trial. Setting : Outpatients with type 2 diabetes from Durango, city in northern Mexico Subjects : 82 subjects between 40 and 75 years of age with type 2 diabetes serum magnesium deficiency and uncomplicated hypertension.
Interventions : During 4 months the intervention group received 2.5 gr of magnesium chloride (50 ml of a solution containing 50 gr of MgCl2 by 1000 ml of solution ). Controls received inert placebo.
Main outcome measure: Change in blood pressure. Increase of serum magnesium Secondary outcomes measures: Changes in lipid profile
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus High Blood Pressure Hypomagnesemia||Dietary Supplement: Magnesium chloride Other: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||85 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Hypomagnesemia as a Risk Factor for Development of Metabolic Syndrome|
|Study Start Date :||July 2006|
|Actual Primary Completion Date :||August 2007|
|Actual Study Completion Date :||November 2007|
Active Comparator: 1
Dietary Supplement: Magnesium chloride
Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
Placebo Comparator: 2
Subjects in the control group received inert placebo once per day during 4 months
- Reduction in the systolic and diastolic blood pressures [ Time Frame: 2 y ]
- Average increase of serum magnesium levels Changes in lipid profile [ Time Frame: 2 y ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00603499
|Biomedical Research Unit|
|Durango, Mexico, 34067|
|Principal Investigator:||Martha Rodriguez-Moran, MD, MSc, PhD||Instituto Mexicano del Seguro Social|